FDA Clearance Tracker · P040047-S070
Coaptite Injectable Implant
Last checked: Nov 20, 2026Latest source record: Jan 25, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jan 25, 2024
Approved
Time to decision
365 days
Received Jan 25, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P040047-S070
- Device name
- Coaptite Injectable Implant
- Applicant
- Merz North America, Inc.
- Applicant location
- Franksville, WI
- Received
- Jan 25, 2023
- Decided
- Jan 25, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P040047
Device type
- Device class
- Class III
- Specialty
- GI, Urology & NephrologyUrology
FDA's approval statement
As written in FDA's record.
Approval for a change to the in-process testing to determine moisture.
Source documents
Other decisions for Merz North America, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250016 · Decided Jul 9, 2026 · 387 days after receipt
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
6 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.